Please sign in to follow a disease.
Malignant endocrine neoplasm
MONDO:0021069A malignant neoplasm affecting the endocrine glands. Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.
Also known as: endocrine neoplasm, Endocrine tumour, cancer of endocrine gland, endocrine cancer, endocrine gland cancer, endocrine neoplasm, malignant, malignant endocrine gland neoplasm, malignant endocrine gland tumor
4871 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 809 trials in this tab.
-
Custom-Made cancer vaccine tested in 25 patients
⭐️ VACCINE ⭐️ CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase: PHASE1 • Sponsor: Aaron Miller • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Could drug holidays improve thyroid cancer treatment?
Disease control CompletedThis study compares two ways of taking the drug pazopanib for people with advanced differentiated thyroid cancer that no longer responds to radioactive iodine. One group takes pazopanib continuously, while the other takes planned breaks and restarts the drug only if the cancer pr…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New cocktail of drugs aims to tackle tough lung cancer
Disease control CompletedThis phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double-Barreled chemo attack on bile duct cancer shows promise
Disease control CompletedThis study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
Disease control CompletedThis study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer from coming back
Disease control CompletedThis study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high r…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for kids with liver cancer: personalized treatment shows promise
Disease control CompletedThis study tests a treatment plan tailored to each child's risk level for a rare liver cancer called hepatoblastoma. About 236 children will receive standard treatments like surgery and chemotherapy, plus the drug temsirolimus for high-risk cases. The goal is to see if this appro…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
Disease control CompletedThis trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prosta…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Phase: PHASE1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
Disease control CompletedThis clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug naderin may help patients fight infections during cancer and TB therapy
Disease control CompletedThis study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…
Phase: PHASE2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy duo before liver surgery shows promise against cancer
Disease control CompletedThis trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…
Phase: PHASE1, PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise in liver cancer trial
Disease control CompletedThis phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically re…
Phase: PHASE2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo shows promise for tough lung cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs—ivonescimab (AK112) and irinotecan liposome—in 60 people with extensive-stage small-cell lung cancer whose disease had worsened after standard first-line therapy. The goal was to see if the combo could slow cancer growth and sh…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a Pre-Surgery drug improve thyroid cancer outcomes?
Disease control CompletedThis study tested whether giving the drug lenvatinib before surgery helps remove advanced thyroid cancer more completely. 29 adults with invasive thyroid cancer took lenvatinib for a short time before their operation. The goal was to see if more patients could have clear or nearl…
Phase: PHASE2 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Lung cancer trial tests two new combo therapies against tough disease
Disease control CompletedThis phase II trial studied 168 people with extensive-stage small cell lung cancer. Researchers added either vismodegib or cixutumumab to standard chemotherapy (cisplatin and etoposide) to see if these combinations worked better than chemo alone. The goal was to slow cancer growt…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control CompletedThis study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
One-Patient trial tests keytruda for rare ovarian cancer
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) as a follow-up treatment for one patient with a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The goal was to see if the drug could help keep the cancer from coming back. Beca…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for tough cancers
Disease control CompletedThis study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…
Phase: PHASE1, PHASE2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Liver cancer drug combo shows promise in large trial
Disease control CompletedThis study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Fish oil supplement tested for muscle loss in liver cancer patients
Disease control CompletedThis completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…
Phase: NA • Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail of drugs shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of three drugs—camrelizumab, apatinib, and chemotherapy (gemcitabine plus cisplatin)—in 49 people with advanced biliary tract cancer that could not be removed by surgery. The goal was to see if the combo is safe and how well it shrinks tumors. Resu…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy shows promise for aggressive lung cancer
Disease control CompletedThis study tested whether adding an experimental drug (BMS-986012) to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer growing. The trial involved 135 newly diagnosed patients. Researchers measured saf…
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to stop liver cancer recurrence after surgery
Disease control CompletedThis study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Modified virus injected into tumors shows promise for liver cancer
Disease control CompletedThis phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients h…
Phase: PHASE2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
Disease control CompletedThis small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…
Phase: PHASE2 • Sponsor: Howard S Hochster • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo tested for tough lung cancer – modest hopes
Disease control CompletedThis study looked at adding sunitinib malate (a drug that blocks tumor blood flow) to standard chemotherapy for people with extensive-stage small cell lung cancer. The trial involved 156 participants and aimed to find the best dose and see if maintenance sunitinib after chemo cou…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo approach before surgery may improve outcomes for massive liver tumors
Disease control CompletedThis study looked at 715 patients with very large liver cancers (over 10 cm) to see if giving a combination of local treatments (like chemo directly into the liver) and body-wide treatments (targeted drugs and immunotherapy) before surgery helps them live longer. Patients were di…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Cancer patients get continued access to promising targeted therapy
Disease control CompletedThis study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising drug cocktail targets Hard-to-Treat liver cancer
Disease control CompletedThis study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options f…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Virus therapy takes on liver cancer in major trial
Disease control CompletedThis study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…
Phase: PHASE3 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental vaccine targets Hard-to-Treat cancers in first human test
Disease control CompletedThis early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Heat zaps tiny thyroid tumors, no scalpel needed
Disease control CompletedThis study tested a procedure called radiofrequency ablation, which uses heat to destroy small thyroid cancers. 27 adults with low-risk papillary thyroid microcarcinoma who did not want surgery or active monitoring took part. The goal was to see if the treatment could eliminate t…
Sponsor: Premier G Med Cardio Kft • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug MK-1200 tested in advanced cancer patients
Disease control CompletedThis study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a flavonoid combo reverse liver scarring and prevent cancer in hepatitis b?
Disease control CompletedThis completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …
Phase: PHASE4 • Sponsor: Trieu, Nguyen Thi, M.D. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…
Phase: PHASE2 • Sponsor: Tae Won Kim • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Cancer drug safety checked in Long-Term study
Disease control CompletedThis study looked at the long-term safety of several cancer drugs, including tislelizumab and pamiparib, in 404 people with advanced cancers. Participants had already been in an earlier trial of these drugs. The goal was to track serious side effects and see if patients could kee…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy combo shows promise for tough pituitary tumors
Disease control CompletedThis phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug may tame Life-Threatening side effects of cancer immunotherapy
Disease control CompletedThis study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how m…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo for liver cancer passes safety check in 1,200 patients
Disease control CompletedThis study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and h…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Personalized vaccine plus immunotherapy shows promise for tough lung cancer
Disease control CompletedThis study tested whether adding a personalized dendritic cell vaccine to the immunotherapy drug atezolizumab could help people with extensive-stage small cell lung cancer stay stable longer after initial chemotherapy. Twenty participants received standard chemo plus atezolizumab…
Phase: PHASE1, PHASE2 • Sponsor: Instituto Oncológico Dr Rosell • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Shorter radiation may be as effective for lung cancer
Disease control CompletedThis study tested whether a shorter course of radiation (hypofractionated) given with chemotherapy works as well as the standard longer radiation course for people with limited-stage small cell lung cancer. 860 adults aged 18-70 with early-stage disease took part. The main goal w…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail may make inoperable liver cancer removable
Disease control CompletedThis study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New radiation technique aims to protect memory in lung cancer patients
Disease control CompletedThis study tested whether avoiding the hippocampus during whole-brain radiation could reduce memory side effects in people with small cell lung cancer. Over 400 patients received either standard whole-brain radiation or a version that spares the hippocampus. The goal was to see i…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody combo takes on advanced cancers in first human trial
Disease control CompletedThis early-stage trial tested an experimental drug called LVGN6051, which activates immune cells by targeting CD137, both alone and combined with the approved immunotherapy Keytruda. The study involved 105 adults with advanced or metastatic cancers that had spread. The main goal …
Phase: PHASE1 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Zapping tumors with precision radiation may help control limited metastatic breast cancer
Disease control CompletedThis study looked at whether adding focused radiation (SBRT) or surgery to standard treatments like chemo or hormone therapy helps people with breast cancer that has spread to just one or two places. 129 participants were randomly assigned to get standard care alone or standard c…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immunotherapy cocktail before surgery shows promise against tough cancers
Disease control CompletedThis study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New antibody combo tackles Hard-to-Treat cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called LVGN7409, which boosts the immune system to fight cancer. It was given alone or with other immune-boosting drugs to 66 adults with advanced cancers that had stopped responding to standard treatments. The main goal was to find the sa…
Phase: PHASE1 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Virus injection targets liver tumors in early trial
Disease control CompletedThis early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…
Phase: PHASE1 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Promising combo therapy for incurable liver cancer shows potential in phase 3 trial
Disease control CompletedThis study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New radioactive compound shows promise in targeting Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new radioactive drug called 177Lu-CTR-FAPI in 12 people with advanced solid tumors (breast cancer, sarcoma, or thyroid cancer) that had spread and no longer responded to standard treatments. The main goals were to see if the drug is safe and how it…
Phase: EARLY_PHASE1 • Sponsor: Lanzhou University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental cancer drug NEV801 enters first human tests
Disease control CompletedThis early-phase trial tested an experimental drug called NEV801 in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The drug was given by IV in increasing doses to find the safest dose and to see if it had any anti-cancer effects. The stud…
Phase: PHASE1 • Sponsor: Neovia Oncology Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for tough lung cancer: LAGOON trial tests powerful drug combo
Disease control CompletedThis study tested two new treatments for people with small cell lung cancer that came back after initial chemotherapy. The experimental drugs, lurbinectedin alone or with irinotecan, were compared to standard treatments (topotecan or irinotecan). The goal was to see if the new op…
Phase: PHASE3 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy shows promise in controlling advanced liver cancer
Disease control CompletedThis study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cancer drug LBL-033 tested in 26 patients – safety first
Disease control CompletedThis study tested a new drug called LBL-033 in 26 adults with advanced malignant tumors that had not responded to other treatments. The main goals were to find a safe dose and check for serious side effects. Researchers also looked at how the drug moves through the body and wheth…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for tough prostate cancers
Disease control CompletedThis study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…
Phase: PHASE1, PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immunotherapy plus precision radiation shows promise for rare skin cancer
Disease control CompletedThis phase II trial tested whether adding stereotactic body radiation therapy (SBRT) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Nine patients with metastatic disea…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Radioactive beads show promise for liver tumors in french registry
Disease control CompletedThis completed registry tracked 332 liver cancer patients in France who received SIR-Spheres, tiny radioactive beads injected into the liver's blood supply to target tumors. The goal was to see how this treatment is used in everyday practice and to monitor safety and survival. Re…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for Chemo-Resistant lung cancers?
Disease control CompletedThis study tested a pill called abemaciclib in 14 people with certain lung cancers (like small cell lung cancer) that stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors and to check its safety. While the drug targets a specific protein to slow…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a triple therapy beat back tough liver cancer?
Disease control CompletedThis completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…
Phase: PHASE1, PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Yeast vaccine shows promise in stopping Cancer's return
Disease control CompletedThis early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …
Phase: PHASE1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo shows early promise against Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise in early liver cancer trial
Disease control CompletedThis early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein t…
Phase: PHASE1 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a gout drug protect kidneys in cancer patients?
Disease control CompletedThis study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.
Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough thyroid cancers? cabozantinib trial shows promise
Disease control CompletedThis study tested the drug cabozantinib in 41 adults with advanced differentiated thyroid cancer that no longer responds to radioactive iodine treatment. Participants took a 60 mg pill daily until their cancer worsened or side effects became too severe. The main goal was to under…
Phase: PHASE2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Radiation may buy time for liver cancer patients before stronger meds needed
Disease control CompletedThis study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Exergaming and mediterranean diet tested for thyroid cancer recovery
Disease control CompletedThis study looked at whether playing active video games (exergaming) and following a Mediterranean diet could help people who had their thyroid removed due to cancer. 80 adults were split into four groups: one did exergaming, one followed the diet, one did both, and one had no ex…
Phase: NA • Sponsor: Nabil Mahmoud Ismail Abdel-Aal • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug ProAgio tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new drug, ProAgio, in 46 people with advanced solid tumors, including pancreatic cancer, who had already tried other treatments. The main goal was to find a safe dose and check for side effects. The study did not aim to cure the disease, but to con…
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New flavored drink helps cancer patients keep weight on during treatment
Disease control CompletedThis study tested three flavors of Supportan® drink (Tropical Fruits, Cappuccino, and Pineapple-Coconut) in 123 cancer patients undergoing chemotherapy, radiotherapy, immunotherapy, or targeted therapy. Patients drank two bottles daily for four weeks alongside their normal diet. …
Phase: NA • Sponsor: Fresenius Kabi Taiwan Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Keytruda may keep liver cancer at bay after surgery
Disease control CompletedThis large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise for tough-to-treat liver cancer
Disease control CompletedThis study tested a combination of proton beam radiotherapy followed by two drugs (Tecentriq and Avastin) in 63 adults with advanced liver cancer that had spread into the portal vein. The goal was to see if this approach could help control the cancer and improve survival. Partici…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—vemurafenib, cetuximab, and irinotecan—in 47 people with advanced solid tumors that have a specific BRAF V600 mutation and could not be removed by surgery or had spread. The main goal was to find the safest dose and under…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radiation zaps liver tumors in patients too sick for surgery
Disease control CompletedThis pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to d…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for advanced liver cancer
Disease control CompletedThis study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for intermediate liver cancer
Disease control CompletedThis study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for cancer patients when immunotherapy fails?
Disease control CompletedThis early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…
Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Liver cancer patients get new hope: study tests two drug cocktails after first treatment fails
Disease control CompletedThis study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works bet…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help pat…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New antibody drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called TQB2210 in 16 people with advanced cancers that had not responded to other treatments. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on cancer cells to block their growth. The main goals were to find a saf…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy drug shows promise in bile duct cancer trial
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Double antenna ablation shows promise for small liver tumors
Disease control CompletedThis study tested a new way to destroy small liver tumors using two microwave antennas at once, compared to the standard single antenna method. Twenty patients with small hepatocellular carcinoma (liver cancer) were treated. The goal was to see if the two-antenna approach could m…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope: hepatitis c drugs after liver cancer treatment
Disease control CompletedThis study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…
Phase: PHASE3 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New needle combo zaps returning liver tumors after failed chemo
Disease control CompletedThis study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One h…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New triple therapy shows promise for aggressive lung cancer
Disease control CompletedThis study tested a combination of two drugs (durvalumab and anlotinib) plus standard chemotherapy as a first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer. 34 adults took part. The goal was to see if the combo helps delay cancer growth o…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New chemo cocktail shows promise against tough bile duct cancer
Disease control CompletedThis study tested two different chemotherapy drug combinations in 92 people with advanced bile duct or gallbladder cancer that could not be removed by surgery. The goal was to see which combination better kept the cancer from growing for at least 6 months. Participants received e…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibiotic cocktail aims to beat infections in cancer patients
Disease control CompletedThis phase II trial tested whether a newer antibiotic combination (imipenem-relebactam) works better than standard antibiotics for treating fever caused by low white blood cell counts in cancer patients. About 100 adults with cancer or who had a stem cell transplant took part. Th…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
HIV patients with liver failure get new drug combo tested in transplant study
Disease control CompletedThis study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for bile duct cancer: triple therapy shows promise after chemo fails
Disease control CompletedThis Phase 2 trial tested a combination of three treatments—local chemotherapy delivered via beads into the liver, a targeted drug called apatinib, and an immunotherapy (PD-1 antibody)—in 20 patients with advanced bile duct cancer that had worsened after standard first-line chemo…
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy shows promise in tough lung cancer battle
Disease control CompletedThis study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Radioactive oil injection may keep liver cancer at bay
Disease control CompletedThis phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Triple immunotherapy cocktail shows promise against tough cancers
Disease control CompletedThis study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Gentle tai chi may help cancer survivors kick the habit
Disease control CompletedThis completed trial tested an online Tai Chi program to help cancer survivors stop smoking. Sixty-eight participants practiced slow movements and breathing exercises over 8 weeks, with their progress tracked via carbon monoxide tests and surveys. The goal was to see if this gent…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Surgeons test wrapping trick to prevent pancreatic leaks after whipple
Disease control CompletedThis study tested a new way to reconnect the pancreas to the intestine during Whipple surgery for certain cancers. The new method uses a stent and wraps the connection with omentum (fatty tissue) to try to prevent leaks. 48 patients were split into two groups to compare the new t…
Phase: NA • Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental drug BAT8010 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug duo shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs, LBL-007 and tislelizumab, in 98 adults with advanced solid tumors. The goal was to see if the combo is safe, tolerable, and effective at shrinking tumors. Researchers also looked at how the drugs move through the body and whether they…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New program aims to cut heart disease risk in young cancer survivors
Disease control CompletedThis study tested a weight management program for young adult cancer survivors (ages 18-39) who have obesity and are within 5 years of finishing cancer treatment. The program combined healthy eating, physical activity, and symptom management to help reduce cardiovascular disease …
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Double attack on liver cancer: does adding RFA to TACE improve survival?
Disease control CompletedThis phase 3 trial tested whether adding radiofrequency ablation (RFA) to standard transarterial chemoembolization (TACE) improves outcomes for people with intermediate-stage liver cancer. 241 participants with 2-10 liver tumors were randomly assigned to receive either TACE alone…
Phase: PHASE3 • Sponsor: Ming Zhao • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis phase II trial tested whether giving the immunotherapy drug tislelizumab, alone or combined with the targeted therapy lenvatinib, before surgery could help shrink liver tumors in 36 patients with resectable hepatocellular carcinoma. The main goal was to see if at least half …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Phase: NA • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer injection shows promise in early trial
Disease control CompletedThis early-stage study tested an experimental drug called JCXH-211, which is injected directly into tumors. It involved 19 adults with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose, while also watc…
Phase: PHASE1 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Precision radiation zaps untreatable liver tumors in tiny pilot study
Disease control CompletedThis study tested a procedure called selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres) in one patient with liver cancer that could not be removed by surgery. The goal was to see if a flexible dosing approach could improve outcomes like tumor …
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy combo shows promise for tough bile duct cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Acid lock could fight blood infections in cancer patients
Disease control CompletedThis study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces tre…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy-Ablation combo shows promise in early liver cancer trial
Disease control CompletedThis study tested whether giving the immunotherapy drug pembrolizumab before and after a standard tumor-destroying procedure (ablation) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the combination could shrink tumors and delay recurre…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy shows promise for hard-to-treat thyroid cancer
Disease control CompletedThis study tested whether combining targeted drugs (trametinib and dabrafenib) with radioactive iodine can help shrink or control advanced thyroid cancer that has stopped responding to standard radioactive iodine treatment. The trial enrolled 40 adults with specific gene mutation…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy shows promise in liver cancer battle
Disease control CompletedThis study tested a new combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib for people with advanced liver cancer who had not received prior treatment. The goal was to see if the combination could help patients live longer or shrink tumors more ef…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for advanced gut cancers? early trial tests targeted antibody
Disease control CompletedThis early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…
Phase: PHASE1 • Sponsor: Arbele Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo tackles tough liver cancer in tiny trial
Disease control CompletedThis small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. Because it was a very early phase 1 trial with very…
Phase: PHASE1 • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill takes on stomach cancer in first human trial
Disease control CompletedThis study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Daily Low-Dose chemo tested for patients with no other options
Disease control CompletedThis study tested two treatments for people with advanced cancer who cannot have standard therapy. One group took a low-dose chemotherapy pill (cyclophosphamide) daily, and the other took a hormone pill (megestrol). The goal was to see which treatment could slow cancer growth for…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo chemo regimen shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a combination of two chemotherapy drugs—weekly paclitaxel given through a vein and daily oral cyclophosphamide—in 28 adults with advanced cancer who had no other treatment options. The goal was to find the safest dose of paclitaxel when used with a f…
Phase: PHASE1 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for lymphoma patients after CAR T-Cell failure
Disease control CompletedThis study tested a drug called glofitamab in 67 people with certain types of lymphoma (a blood cancer) that did not respond to or came back after CAR T-cell therapy. Participants received a pre-treatment followed by up to 11 cycles of glofitamab. The goal was to see if this anti…
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental combo for bile duct cancer shows promise in tiny trial
Disease control CompletedThis phase 2 study tested a combination of two drugs, durvalumab and SNDX-6352, in 5 people with advanced bile duct cancer that had not spread beyond the liver. Participants first received standard chemo or radiation therapy directly into the liver, then the drug combination. The…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
High-dose radiation beams target liver tumors with precision
Disease control CompletedThis study tested a high-precision radiation treatment called stereotaxic radiotherapy (CyberKnife) in 44 adults with a single liver cancer tumor. The goal was to stop the tumor from growing for at least 18 months. Participants received three high-dose radiation sessions over 8-1…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill HRS7415 shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called HRS7415 in 38 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see if the drug could help control the disease. Researchers monitored side effects and measured drug levels in…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase: PHASE1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of the targeted drug regorafenib with chemotherapy (mGEMOX) in 66 people with advanced bile duct cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effects. This is not a cure, but aims to cont…
Phase: PHASE1, PHASE2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immunotherapy drug shows limited promise in tough bile duct cancer
Disease control CompletedThis phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 54 patients with advanced biliary tract cancer that had stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors. While nivolumab is approved for other cancers, it is not yet app…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immunotherapy-Radiation combo shows promise in tough lung cancer
Disease control CompletedThis early-phase trial tested the safety and best dose of the immunotherapy drug pembrolizumab when combined with chemotherapy and radiation for people with small cell lung cancer. The goal was to see if adding pembrolizumab helps the immune system fight the cancer more effective…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for liver cancer: triple therapy shows promise
Disease control CompletedThis study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…
Phase: PHASE2, PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Lenvatinib under the microscope: safety check for tough thyroid cancers
Disease control CompletedThis study looked at the safety of the drug lenvatinib in 50 people with advanced thyroid cancer that had stopped responding to radioactive iodine treatment. Researchers tracked side effects and how often patients needed to lower their dose. They also checked whether tumors shran…
Phase: PHASE4 • Sponsor: Eisai Pharmaceuticals India Pvt. Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New bispecific antibody shows promise for unresectable liver cancer
Disease control CompletedThis phase II trial tested a drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. AK112 is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth. The study measured safety and how well the drug shrank …
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a simple drink fix a complication of cancer surgery?
Disease control CompletedThis phase 2 trial tested whether taking iohexol by mouth can treat chylous ascites, a leak of lymphatic fluid that can happen after abdominal or pelvic cancer surgery. The study enrolled 42 patients who developed this condition after surgery. The goal was to see if oral iohexol …
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Targeted drug shows promise for rare bile duct cancer
Disease control CompletedThis study tested an experimental drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). Participants had already tried chemotherapy without success. The goal was to see if the drug could shrink tumors. Results help determ…
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Real-World check: does zepzelca help advanced lung cancer patients?
Disease control CompletedThis study followed 272 adults with extensive-stage small cell lung cancer who were taking the drug Zepzelca. Researchers wanted to see how well the drug worked and how safe it was in real-world settings, not just in controlled trials. The goal was to measure tumor shrinkage, sur…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy shows promise for tough-to-treat liver cancer
Disease control CompletedThis study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver (HAIC) in 30 adults with advanced liver cancer that had spread into the main portal vein. The goal was to see if the combination could improve one-year survival.…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Keyhole vs. open surgery: which is safer for pancreatic cancer?
Disease control CompletedThis study compared two surgical methods—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called periampullary adenocarcinoma. Forty patients were enrolled to see which approach led to fewer complications like pancreatic fistula. The goal was t…
Phase: NA • Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug targets rare gene mutations in advanced cancers
Disease control CompletedThis phase II trial tested the drug infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The study measured how many patients' tumors shrank or stabili…
Phase: PHASE2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise in controlling advanced cancers
Disease control CompletedThis study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Rapid Finger-Prick test could help shield cancer patients from COVID-19
Diagnosis CompletedThis study tested a quick finger-prick blood test to see if cancer patients had been infected with COVID-19 in the past. Researchers enrolled 214 adults being treated for cancer. The goal was to find out how many had antibodies, including those without symptoms, to help clinics k…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New PET tracer could spot hidden thyroid cancer
Diagnosis CompletedThis study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tr…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New blood test may spot liver cancer sooner in High-Risk patients
Diagnosis CompletedThis study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …
Phase: NA • Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New biopsy technique may spot hidden abdominal cancers without major surgery
Diagnosis CompletedThis study looked at how well a special biopsy method called EUS-FNB can diagnose hard-to-reach tumors in the abdomen, such as those near the bile duct or small intestine. Researchers reviewed data from 131 patients who had this procedure over 10 years. The goal was to see if thi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New handheld device could spot heart and diabetes problems in cancer patients
Diagnosis CompletedThis study tested a handheld device that uses a single wave to measure how well the heart pumps blood and how stiff the arteries are. Researchers compared it to standard echocardiography in 159 cancer patients. The goal was to see if the device could also help identify patients a…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
AI and PET scans join forces to grade cancer without a biopsy
Diagnosis CompletedThis completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …
Sponsor: Ciprian Catana, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Which biopsy method best spots bile duct cancer?
Diagnosis CompletedThis study looked at different ways to take tissue samples from the bile duct during a procedure called ERCP. The goal was to see which method is most accurate for finding cancer. 327 adults with unclear bile duct narrowing took part. Researchers compared several biopsy technique…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New ultrasound trick spots liver cancer treatment success days earlier
Diagnosis CompletedThis study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
AI takes on radiologists: can a computer beat the standard for liver cancer diagnosis?
Diagnosis CompletedThis study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Minutes, not days: new rapid test could speed up thyroid cancer detection
Diagnosis CompletedThis study tested a new rapid test that checks for thyroid cancer spread to neck lymph nodes in just minutes, instead of the usual days-long wait. Researchers studied 250 adults with suspected or known thyroid cancer, comparing the quick test to standard lab methods. The goal was…
Sponsor: Soroka University Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New blood markers could revolutionize liver cancer diagnosis
Diagnosis CompletedThis study looked at blood samples from 573 people to find new markers that could diagnose liver cancer more accurately. Researchers compared samples from patients with liver cancer, those with other liver conditions, and people with hepatitis infections. The goal is to improve u…
Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Blow into this tube: a simple breath test might spot liver disease early
Diagnosis CompletedThis study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
AI outperforms some doctors in spotting thyroid cancer on ultrasound
Diagnosis CompletedThis study tested an artificial intelligence (AI) system called Vision-LSTM to see if it could accurately diagnose a specific type of thyroid nodule (TI-RADS 4b) from ultrasound images. Researchers used images from 401 patients and compared the AI's performance to that of junior …
Sponsor: Ma Zhe • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
New blood test could spot hidden liver cancer early
Diagnosis CompletedThis completed study tested a new blood test that looks for tiny particles called exosomal microRNAs to detect intrahepatic cholangiocarcinoma, a rare and aggressive liver cancer. Researchers analyzed blood samples from 535 adults to see how accurately the test could identify can…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New blood test could spare bile duct cancer patients unnecessary surgery
Diagnosis CompletedThis study tested a new blood test called LyMIC that looks for tiny particles (exosomes) released by cancer cells. The goal was to see if it could accurately tell whether bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Spinal injection may shield brain from lymphoma spread
Prevention CompletedThis study tested a chemotherapy drug called thiotepa, given via spinal injection, to prevent lymphoma from spreading to the brain or spinal cord in people with high-risk diffuse large B-cell lymphoma (DLBCL). 31 participants received the treatment and were followed for 2 years t…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Simple relaxation technique may improve sleep in cancer patients
Symptom relief CompletedThis study tested whether Benson relaxation exercises can improve sleep quality in cancer patients. 72 adults with cancer were randomly assigned to do relaxation exercises or receive a sleep hygiene booklet. The goal was to see if this simple, non-drug method could help with slee…
Phase: NA • Sponsor: Atlas University • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Acupressure may ease fatigue in young cancer survivors
Symptom relief CompletedThis study tested whether young cancer survivors (ages 15-39) could learn to do acupressure on themselves to reduce fatigue. 42 people who had finished cancer treatment at least three months ago and still felt tired took part. They used a special tool and a phone app to apply pre…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Buzzy, coaching, or kaleidoscope: which best calms kids during cancer shots?
Symptom relief CompletedThis study tested three non-drug methods to reduce pain, fear, and anxiety during subcutaneous injections in 45 children aged 6–12 with cancer. The approaches were Buzzy® (a device that vibrates and cools the skin), a cognitive-behavioral coaching package, and a kaleidoscope for …
Phase: NA • Sponsor: Kocaeli University • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Short physiotherapy program shows promise for palliative cancer patients
Symptom relief CompletedThis study tested whether a one-week physiotherapy program could improve movement, walking, and daily independence in 32 advanced cancer patients receiving palliative care. The program included exercises, mobility training, and breathing therapy tailored to each patient. Research…
Phase: NA • Sponsor: University of Jazan • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Pump education eases chemo anxiety, study finds
Symptom relief CompletedThis study looked at whether teaching cancer patients about their portable chemotherapy pump (elastomeric pump) can make them feel more comfortable and less anxious. 70 adults receiving 5-FU treatment were split into two groups: one got extra education and a booklet, the other go…
Phase: NA • Sponsor: Biruni University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Punjabi cancer patients get a custom exercise boost
Symptom relief CompletedThis pilot study tested whether a 12-week exercise program designed for Punjabi-speaking South Asian cancer patients and their support persons is practical and well-liked. Twelve participants did twice-weekly exercise sessions and filled out questionnaires. The goal was to see if…
Phase: NA • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New drip combo aims to stop chemo nausea in kids
Symptom relief CompletedThis phase 3 trial tested whether giving a continuous, slow infusion of ondansetron (a common anti-nausea drug) plus dexamethasone (a steroid) could better control nausea and vomiting in children undergoing chemotherapy. The study enrolled 28 children aged 1 day to 18 years with …
Phase: PHASE3 • Sponsor: Immune Oncology Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Inner strength boosts morale in elderly cancer patients
Symptom relief CompletedThis study tested a one-month program designed to build inner strength in elderly cancer patients who were feeling demoralized. 66 patients took part, with half receiving the program plus standard care and the other half receiving standard care alone. The goal was to see if the p…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Virtual reality goggles could take the sting out of cancer port needles
Symptom relief CompletedThis study tested whether using virtual reality goggles during the insertion of a port needle (a common procedure for chemotherapy) can improve comfort and satisfaction in cancer patients. 92 adults with stage I-III cancer were randomly assigned to either standard care or standar…
Phase: NA • Sponsor: Uludag University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Yoga with a shared background may ease Cancer's toll for black survivors
Symptom relief CompletedThis study tested whether a yoga program taught by a Black instructor could help Black cancer survivors feel better and improve their quality of life. 13 adults who had cancer in the last 5 years took part. The goal was to see if this approach was acceptable and helpful for manag…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New Low-Dose pain patch aims to ease cancer suffering
Symptom relief CompletedThis study tested a low-dose fentanyl patch in 14 cancer patients in Taiwan to see if it is safe and tolerable for managing pain. The patch delivers pain medicine through the skin over 28 days. The main goal was to see how many patients dropped out due to side effects, with the h…
Phase: PHASE4 • Sponsor: Janssen-Cilag Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Cancer pain relief without the sickness: new hope from an old drug
Symptom relief CompletedThis study tested whether naldemedine, a drug already used for opioid-induced constipation, can also prevent nausea and vomiting when cancer patients start strong painkillers. 120 adults with cancer who were beginning opioid therapy took either naldemedine or a placebo for up to …
Phase: PHASE4 • Sponsor: International University of Health and Welfare • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Simple muscle relaxation technique shows promise for thyroid cancer pain
Symptom relief CompletedThis study tested whether a simple relaxation exercise, called progressive muscle relaxation (PMR), could help reduce pain and improve quality of life in people with thyroid cancer. Thirty-two patients undergoing chemotherapy were randomly assigned to do either PMR plus gentle st…
Phase: NA • Sponsor: University of Faisalabad • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Zapping away stress and cigarettes: new hope for cancer survivors
Symptom relief CompletedThis study tested whether a gentle, non-invasive brain stimulation technique called tDCS could help cancer survivors who smoke feel less distressed and smoke fewer cigarettes. 43 participants used the device at home via telehealth. The main goal was to see if people found the dev…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New spanish therapy helps cancer survivors find purpose after treatment
Symptom relief CompletedThis study tested a Spanish adaptation of Meaning-Centered Psychotherapy for 92 adults who completed cancer treatment. The therapy aims to help patients find meaning in life and reduce anxiety. Participants attended eight group sessions focused on sources of meaning, facing the f…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
String-Attached stent may ease bile duct cancer surgery prep
Symptom relief CompletedThis pilot study tested a plastic stent with a retrieval string to drain bile in 40 people with resectable bile duct cancer. The goal was to see if the stent could safely reduce bile buildup before surgery. Researchers measured serious complications and how well the stent worked.
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can learning to solve problems ease cancer distress in young adults?
Symptom relief CompletedThis study tested a program called Bright IDEAS-YA that teaches young adults with cancer a step-by-step approach to solving problems. The goal was to see if it could reduce symptoms of depression and anxiety and improve quality of life. 344 young adults (ages 18-39) newly diagnos…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Laughter yoga: a surprising way to help cancer patients feel better?
Symptom relief CompletedThis study looked at whether laughter yoga could help cancer patients going through chemotherapy. 55 patients were split into two groups: one did weekly 40-minute laughter yoga sessions for four weeks, while the other received standard care. After four weeks, the laughter yoga gr…
Phase: NA • Sponsor: Ataturk University • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can music ease anxiety for End-of-Life cancer patients?
Symptom relief CompletedThis study tested a music therapy program called Meraki for cancer patients receiving palliative care. The goal was to see if three music sessions could improve emotional well-being, reduce anxiety and depression, and boost quality of life. Researchers enrolled 80 patients and me…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New therapy aims to curb opioid misuse in cancer patients
Symptom relief CompletedThis study tested a 6-session therapy called Acceptance and Commitment Therapy (ACT) for cancer patients at risk of opioid misuse. 40 adults with cancer and a high score on an opioid risk tool participated. The goal was to see if the therapy was feasible and acceptable, not yet t…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Cancer patients boost Well-Being by tapping into personal strengths
Symptom relief CompletedThis study tested a 3-week program that helps cancer patients identify their personal strengths (like hobbies, social support, or personal qualities) and use them to cope better. 32 adults with different cancers took part in card-sorting sessions, phone calls, and home exercises.…
Phase: NA • Sponsor: UniDistance Suisse • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Laser and Light-Sensitive drug shrink lung tumors in early trial
Symptom relief CompletedThis early-phase trial tested a treatment called photodynamic therapy for people with advanced lung cancer that blocks airways. Patients received a light-sensitive drug followed by a laser to activate it inside the tumor. The goal was to see if the treatment is safe and can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Writing away worries: new study helps young cancer survivors cope with body image
Symptom relief CompletedThis study tested whether a simple at-home writing program could help teens and young adults (ages 15-39) who finished cancer treatment feel less distressed about their body image and reduce anxiety. Thirty survivors participated in a four-week expressive writing program. The goa…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Coloring away chemo sickness: mandala therapy shows promise
Symptom relief CompletedThis study tested whether coloring mandala patterns can reduce nausea, vomiting, and fatigue, and improve psychological well-being in cancer patients receiving chemotherapy. 85 patients were split into a coloring group and a control group. The coloring session lasted 20-30 minute…
Phase: NA • Sponsor: University of Gaziantep • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Can an online wellness program ease anxiety in chronic disease?
Symptom relief CompletedThis study tested a 12-week online mind-body program for adults with chronic conditions like heart failure, cancer, and liver disease. The program included mindful movement, meditation, breathwork, and coping skills. Researchers measured changes in anxiety, depression, fatigue, a…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Green tea extract tested as a frailty fighter for older cancer survivors
Symptom relief CompletedThis pilot study tested whether taking a green tea extract (EGCG) plus vitamin C daily for 12 weeks is safe and feasible for older cancer survivors who are frail or pre-frail. The study enrolled 24 people aged 65 and older who had completed cancer treatment. The main goal was to …
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Eating smart during cancer: study tests nutrition lessons
Symptom relief CompletedThis study looked at whether a structured nutrition education program can improve how much and how well cancer patients eat. 80 adults on active cancer treatment were split into two groups: one received personalized nutrition advice, the other did not. Researchers measured their …
Phase: NA • Sponsor: Istanbul Aydın University • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
VR headsets may calm chemo patients
Symptom relief CompletedThis study tested whether using a virtual reality headset during chemotherapy can reduce distress, anxiety, and pain. 68 cancer patients were randomly assigned to either use VR for 15–30 minutes or receive standard care. Researchers measured changes in distress and pain scores be…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
App helps kids with cancer report symptoms to doctors
Symptom relief CompletedThis study tested a mobile app called SyMon-SAYS that lets children with cancer report their symptoms weekly to their doctors. The goal was to see if using the app helps manage symptoms and improve quality of life. 216 children and their parents took part, with some using the app…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Can a Stress-Management program help young cancer patients cope?
Symptom relief CompletedThis study tested whether a program called PRISM (Promoting Resilience in Stress Management) could help young adults aged 18-39 who have cancer or desmoid tumors manage anxiety and depression. The program teaches skills like stress management, goal setting, and positive thinking.…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New pill may ease severe cancer pain
Symptom relief CompletedThis study tested an experimental oral drug called Trichomylin® in 11 adults with advanced cancer who had moderate to severe pain despite taking strong opioids. The goal was to see if the drug is safe and can provide additional pain relief. Participants took the drug twice daily,…
Phase: PHASE2 • Sponsor: ZYUS Life Sciences Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Lung cancer patients breathe easier with simple rehab program
Symptom relief CompletedThis study tested an 8-week supervised program of breathing exercises and light strength training for 30 people with advanced lung cancer (stage IIIB/IV) who were also getting chemotherapy. Those in the rehab group could walk farther, breathe better, and reported less coughing an…
Phase: NA • Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Smartwatches and exercise advice offer new hope for cancer fatigue
Symptom relief CompletedThis study tested a system that helps cancer patients manage fatigue. Patients used a phone app to report their tiredness and wore a smartwatch to track activity. Based on their fatigue level, they received personalized exercise advice. The goal was to see if this approach could …
Phase: NA • Sponsor: Taipei Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Light strokes, big relief? touch therapy eases cancer fatigue
Symptom relief CompletedThis study tested whether a gentle, light-touch therapy (therapeutic touch) could help advanced cancer patients in palliative care sleep better and feel less tired. Sixty-one patients were randomly assigned to receive either 5 days of 10-15 minute touch sessions or standard care.…
Phase: NA • Sponsor: Erzurum Technical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can a Zoom-Based resilience program ease caregiver stress?
Symptom relief CompletedThis study tested a 9-session virtual mind-body program (SMART-3RP) to see if it helps caregivers of cancer survivors feel less stressed and more resilient. It compared the program to a standard online support group. The trial enrolled 94 participants and focused on whether the p…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Better sleep for cancer patients and their partners: a new approach
Symptom relief CompletedThis study tested a sleep improvement program for people with cancer and their intimate partners who also have sleep problems. The goal was to reduce insomnia and improve sleep quality. Only 2 couples took part, so results are very limited.
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New online tool helps cancer patients get better sleep
Symptom relief CompletedThis study tested an online program to help cancer patients with insomnia. It included 348 adults with cancer who had trouble sleeping. The program used cognitive-behavioral techniques and aimed to see who might need extra help from a professional.
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Can a smartphone app help cancer survivors kick the habit?
Symptom relief CompletedThis completed Phase 1 trial tested a smartphone app that uses mindfulness exercises to help cancer survivors quit smoking. Twelve participants used the app daily for three weeks, completed surveys, and received nicotine patches. The goal was to see if people liked the app and fo…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Zapping acupoints may calm chemo sickness
Symptom relief CompletedThis study tested whether mild electrical pulses on specific acupoints could reduce nausea and vomiting caused by cisplatin chemotherapy. Thirty-four cancer patients received the stimulation during treatment. The goal was to see if this drug-free approach could ease these common …
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Team nursing approach shows promise for lung cancer patients on immunotherapy
Symptom relief CompletedThis study tested a team-based nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program included close monitoring for side effects, help with medication adherence, nutrition and exercise support, and psychological …
Phase: NA • Sponsor: Shanxi Province Cancer Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Spinal pump may ease cancer pain when pills fail
Symptom relief CompletedThis study tested a device that delivers pain medicine directly to the spinal cord for cancer patients with severe pain not controlled by oral opioids. Researchers compared the pump to standard medical management in 30 adults. The goal was to see if the pump reduces pain intensit…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Laser acupuncture may ease chemo sickness in kids
Symptom relief CompletedThis study tested whether using a low-frequency laser on an acupuncture point (P6) can help prevent nausea and vomiting caused by chemotherapy in children aged 2 to 20. The 30 participants received the laser treatment alongside standard anti-nausea drugs. The goal was to see if a…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Virtual reality offers calm before the radiation storm
Symptom relief CompletedThis pilot study tested whether a 10-minute virtual reality mindfulness program could help cancer patients relax before their radiation simulation. 25 adults scheduled for radiation planning used a VR headset to practice breathing exercises in a calming virtual environment. The m…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New program aims to ease young cancer Survivors' return to everyday life
Symptom relief CompletedThis study tested a program called YATAC, designed to help young adults (ages 18-39) recover from cancer and return to everyday life. The program covers goal-setting, managing daily life, staying active, coping with emotions, education, work, finances, relationships, and peer sup…
Phase: NA • Sponsor: Defactum, Central Denmark Region • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can cutting extra pills help older cancer patients get better chemo?
Symptom relief CompletedThis study tested whether a pharmacist-led program could safely reduce the number of unnecessary medications taken by older adults (65+) with curable cancers starting chemotherapy. 51 patients participated, with oncologists randomly assigned to either a pharmacist review or a sim…
Phase: PHASE1, PHASE2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Tiny scope, big difference? study tests Microscope-Assisted thyroid surgery
Symptom relief CompletedThis study compared two types of thyroid surgery: one using a microscope and the standard approach. Researchers looked at blood loss, nerve damage, and low calcium levels after surgery in 74 patients with thyroid cancer or other thyroid conditions. The goal was to see if the micr…
Phase: NA • Sponsor: Shahida Islam Medical Complex • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Mindfulness may ease stress for liver patients
Symptom relief CompletedThis study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…
Sponsor: Methodist Health System • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Rural cancer survivors get a boost: simple exercise program may improve strength and quality of life
Symptom relief CompletedThis study tested whether a 12-week virtual exercise program could help rural cancer survivors improve their physical function and quality of life. One hundred adults who had completed cancer treatment and lived in rural areas took part. The program focused on cardiovascular endu…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New program aims to boost cancer patients' quality of life with daily emails and biofeedback
Symptom relief CompletedThis study tested a 6-month program called CancerPEP that sends daily emails to cancer patients and survivors with tips on exercise, yoga, stress reduction, and healthy eating. The goal was to see if the program is practical and helps improve mental and physical health. 104 adult…
Phase: NA • Sponsor: Nova Scotia Health Authority • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
New pill could ease carcinoid syndrome Flare-Ups
Symptom relief CompletedThis Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to…
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can a single pill ease pain after liver cancer procedure?
Symptom relief CompletedThis study tested whether giving a single dose of pregabalin before a liver cancer ablation procedure can reduce pain afterward. 70 adults with liver cancer were randomly assigned to receive either pregabalin or a placebo before their procedure. The main goal was to measure pain …
Phase: PHASE4 • Sponsor: Sherief Abd-Elsalam • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Can family therapy ease grief after cancer? new study tests it
Symptom relief CompletedThis study tested whether family-focused grief therapy (FFGT) helps families cope when a member has advanced cancer. 700 families were randomly assigned to standard care, 6 therapy sessions, or 10 sessions. The goal was to prevent depression and improve communication during palli…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Digital coaching eases cancer treatment struggles
Symptom relief CompletedThis study tested an online educational program for cancer patients receiving chemotherapy. The program included video sessions, peer discussions, and digital materials to help with symptom management and emotional coping. Researchers compared 212 patients who used the program to…
Phase: NA • Sponsor: Zagazig University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Pickleball helps cancer survivors get active and feel better
Symptom relief CompletedThis study tested whether a pickleball program is practical and enjoyable for cancer survivors and their family or friends. The goal was to increase physical activity and improve overall wellness. 28 participants joined the program, which involved learning and playing pickleball …
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
Yoga study reveals cancer Patients' preferences for digital vs. studio sessions
Symptom relief CompletedThis study looked at whether cancer patients prefer doing yoga online or in a studio during their treatment. 163 people with cancer chose their preferred setting and attended weekly group yoga for 12 weeks. Researchers measured quality of life and interviewed participants about t…
Phase: NA • Sponsor: Linkoeping University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New incentive program helps cancer patients kick the habit before surgery
Symptom relief CompletedThis study tested a new way to help cancer patients quit smoking before their surgery. 282 adults with cancer or suspected cancer who smoked daily took part. Half received standard counseling and nicotine patches, while the other half also got extra rewards for staying smoke-free…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New shot could stop chemo sickness in its tracks
Symptom relief CompletedThis phase 3 trial tested a drug called APF530, given as a shot, to prevent nausea and vomiting caused by chemotherapy. Over 1,400 cancer patients took part, comparing APF530 with the standard drug Aloxi. The goal was to see if APF530 could keep patients from vomiting or needing …
Phase: PHASE3 • Sponsor: Heron Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New shot may beat standard pill for chemo nausea
Symptom relief CompletedThis phase 3 trial tested whether a new drug called APF530, given as a shot under the skin, works better than the standard drug ondansetron for preventing nausea and vomiting after strong chemotherapy. About 942 cancer patients took part. The study compared both drugs when combin…
Phase: PHASE3 • Sponsor: Heron Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Ancient meets modern: new combo therapy tackles cancer fatigue
Symptom relief CompletedThis study tested a program that mixes traditional Chinese medicine with standard Western hospital care to help reduce cancer-related fatigue. 86 adults with cancer took part while in the hospital. The main goal was to see if their fatigue levels improved from their worst point t…
Phase: NA • Sponsor: Taichung Tzu Chi Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Can a free online class fix insomnia in young cancer survivors?
Symptom relief CompletedThis study tested an online sleep education program for young adult cancer survivors (ages 20-39) who have trouble sleeping. Participants took a single online session, with some also getting extra coaching. The goal was to see if it could reduce insomnia and improve mood. The stu…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New pump could ease cancer pain without heavy drugs
Symptom relief CompletedThis study tested an implantable pump that delivers pain medicine directly into the spinal fluid for people with hard-to-treat cancer pain. Eight patients with advanced cancer and severe pain despite strong opioids took part. The goal was to see if the pump could provide better p…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
PET-CT scans could sharpen radiation targeting for liver tumors
Knowledge-focused CompletedThis study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Family secrets? study maps how relatives talk about genetic health risks
Knowledge-focused CompletedThis study explored how family members share health information about genetic diseases like sickle cell, diabetes, and cancer. Over 1,000 adults completed surveys or interviews about their family health history and support. The goal was to understand social and relational factors…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
Knowledge-focused CompletedThis study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists investigate why adrenal tumors produce hormones
Knowledge-focused CompletedThis study looked at adrenal gland tumors to understand why they form, why some release extra hormones, and why some are cancerous. Researchers studied 690 people with known or suspected adrenal tumors. Participants underwent tests like blood draws, imaging scans, and urine colle…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Cooking up health: new study tests if free produce and lessons help cancer survivors
Knowledge-focused CompletedThis study looks at whether a 12-week program of cooking demonstrations, recipe cards, and free fruit and vegetable bundles can help cancer survivors eat healthier. Only 11 people are taking part, and the main goal is to see if such a program is practical and keeps people interes…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Hidden thyroid cancers: how common are they in patients with thyroiditis?
Knowledge-focused CompletedThis completed study from Minia University looked at 200 patients with autoimmune thyroiditis (an inflamed thyroid) who had thyroid surgery. The goal was to see how often thyroid cancer is found by accident when examining the removed tissue. Researchers checked for cancer in pati…
Phase: NA • Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Radiation safety study aims to personalize thyroid cancer treatment
Knowledge-focused CompletedThis study collects standard-of-care images from people with differentiated thyroid cancer who are treated with radioactive iodine (Iodine-131). The goal is to better understand how much radiation reaches healthy organs and what dose is needed to destroy thyroid tissue. By gather…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Hidden danger: study probes blood clot risk in cancer patients with COVID-19
Knowledge-focused CompletedThis study investigates how often cancer patients with COVID-19 develop dangerous blood clots (venous thromboembolism). Researchers will screen participants using ultrasound and blood tests to detect clots, whether or not they cause symptoms. The goal is to understand the true ra…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can a quick chat with a radiotherapy tech ease cancer patients' anxiety?
Knowledge-focused CompletedThis study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New document helps young adults voice End-of-Life wishes
Knowledge-focused CompletedThis study tested a document called Voicing My CHOiCES, designed to help young adults (ages 18-39) with serious illnesses like cancer or HIV discuss their care preferences. Participants filled out questionnaires about anxiety, social support, and communication, then reviewed the …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
10,000 cancer records analyzed to supercharge future treatments
Knowledge-focused CompletedThis study collects and analyzes health records from 10,000 cancer patients across multiple sites. Researchers will use this real-world data to better understand patient populations, improve clinical trial design, and support drug development. No new treatments are tested—the goa…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New app aims to help cancer patients report side effects from home
Knowledge-focused CompletedThis study tested whether a smartphone app called QuestOnco can reliably track side effects in 134 adult cancer patients receiving active treatment. Patients used the app to report symptoms, and researchers compared those reports to standard paper questionnaires. The goal was to …
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Does anesthesia choice impact liver cancer recurrence?
Knowledge-focused CompletedThis study looked at 153 people having liver cancer surgery to see if the type of anesthesia they received affected their recovery and immune response. Researchers compared different anesthesia methods and measured blood markers related to inflammation and immune cell activity. P…
Phase: NA • Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Real-Time tissue test may help surgeons avoid unnecessary neck dissections in thyroid cancer
Knowledge-focused CompletedThis pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…
Sponsor: Eleonora Lori, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lab study tests antibody that could unlock immune attack on liver cancer
Knowledge-focused CompletedThis completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Your tongue could reveal cancer: AI study analyzes 4,100 people
Knowledge-focused CompletedThis completed study collected tongue images and clinical data from 4,100 people—both cancer patients and healthy individuals—to build a database. Researchers plan to use artificial intelligence to analyze tongue features for early cancer screening and diagnosis. The study did no…
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Study aims to cut hospital time after liver surgery by looking beyond medicine
Knowledge-focused CompletedThis completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Heart MRI may reveal hidden damage in young cancer survivors after sepsis
Knowledge-focused CompletedThis pilot study tested whether a heart MRI could be done safely and effectively in children with cancer who recently had sepsis. The goal was to see if the MRI could find hidden heart inflammation or weakness that standard tests might miss. Only 7 children took part, and the foc…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe Gut-Liver link in alcohol and fatty liver cancers
Knowledge-focused CompletedThis study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a short video boost genetic know-how in pediatric cancer families?
Knowledge-focused CompletedThis study looked at whether an informational video could help parents and teens better understand genetic testing after a new cancer diagnosis. About 355 families from a children's hospital took part. The goal was to see if the video was acceptable and improved knowledge about g…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Can a tailored diet help cancer survivors? new study tests the recipe
Knowledge-focused CompletedThis study tested a nutrition program for cancer survivors who are overweight or have obesity. The program included one-on-one counseling with a dietitian, behavioral skills training, and group support. The goal was to see if the program was easy to run and acceptable to particip…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Zambia study tracks hepatitis b outcomes in hundreds of patients
Knowledge-focused CompletedThis study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Cancer drug opdivo qvantig under the microscope: who gets it and how?
Knowledge-focused CompletedThis completed study reviewed medical records of 200 adults with cancer who received the drug nivolumab (Opdivo) either as an intravenous infusion or as a subcutaneous injection (Opdivo Qvantig) in community oncology clinics across the United States. The goal was to describe the …
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Can cancer patients recover at home with remote monitoring?
Knowledge-focused CompletedThis study tested a program that lets recently hospitalized cancer patients recover at home with remote monitoring of symptoms, vital signs, and weight. The program includes home visits and close communication with the oncology team. Researchers wanted to see if this approach is …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Small study tests best way to mix chemo for liver tumors
Knowledge-focused CompletedThis study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…
Phase: PHASE4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Instacart and nutrition calls may ease food insecurity for cancer survivors
Knowledge-focused CompletedThis study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Cancer Patients' blood thinner mystery solved?
Knowledge-focused CompletedThis study measured how two common blood thinners (rivaroxaban and apixaban) behave in 193 adults with active cancer who also had blood clots or atrial fibrillation. Researchers aimed to understand factors like age, weight, and kidney function that affect drug levels. The goal wa…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
633 PMBCL patients studied: key insights on refractory disease and survival
Knowledge-focused CompletedThis study looked back at 633 people with primary mediastinal large B-cell lymphoma (PMBCL) treated in Italy between 2007 and 2019. Researchers collected data on how well treatments worked, how many patients had disease that didn't respond or came back early, and survival rates. …
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Cancer Patients' own needs may guide better care, study finds
Knowledge-focused CompletedThis completed study at Sohag Oncology Center tested whether a quality-of-life survey could help match cancer patients' needs with the right supportive care, like pain management or nutrition counseling. Over 4,400 adult cancer patients completed the EORTC QLQ-C30 questionnaire, …
Sponsor: Sohag Oncology Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Smart scans and DNA tests could revolutionize liver cancer care
Knowledge-focused CompletedThis study looked at whether combining detailed MRI scans with whole genome sequencing can help doctors choose the best treatment for people with liver cancer. Researchers studied 200 adults who were scheduled for liver surgery. The goal was to see if these advanced tests provide…
Sponsor: Perspectum • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
AI learns to spot cancer pain from faces and voices
Knowledge-focused CompletedThis study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive cancer registry tracks genetic Testing's Real-World impact
Knowledge-focused CompletedThis completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New online tool aims to pick the right patients for cancer drug trials
Knowledge-focused CompletedResearchers tested a new online tool called PIPO that helps doctors estimate how long a cancer patient might live. This information can guide decisions about which patients to enroll in early-phase clinical trials. The study included 586 people who had already joined phase 1 or p…
Sponsor: Vall d'Hebron Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
AI model aims to predict cancer Patients' emergency room visits
Knowledge-focused CompletedThis study tested a machine learning model that uses electronic health records to predict which cancer patients receiving infusion therapy are at risk of needing emergency care or hospitalization within 30 days. Researchers analyzed data from over 4,700 patients at UCSF. The goal…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
VR headsets calm cancer patients before radiation
Knowledge-focused CompletedThis study looked at whether a virtual reality (VR) education program could help first-time radiation therapy patients understand their treatment better and reduce anxiety and depression. 84 cancer patients were split into two groups: one received VR education, the other standard…
Phase: NA • Sponsor: Asia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study aims to fix lack of diversity in cancer trials
Knowledge-focused CompletedThis completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New program aims to break down barriers to cancer trial participation
Knowledge-focused CompletedThis pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Blood tests and surveys may predict cancer treatment success
Knowledge-focused CompletedThis study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Thousands tracked in Largest-Ever liver cancer bead therapy registry
Knowledge-focused CompletedThis registry followed over 1,000 liver cancer patients who received SIR-Spheres—tiny radioactive beads injected into the liver's blood supply to kill tumors. The goal was to see how this treatment is used in real hospitals and how it affects survival, side effects, and quality o…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Study tests whether nudges on social media can stop cancer myths in their tracks
Knowledge-focused CompletedThis completed study looked at whether adding a warning prompt above cancer misinformation posts on social media encourages people to flag them. Researchers recruited 294 US adults who had either been diagnosed with cancer or cared for someone with cancer. Participants saw fake s…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New ultrasound technique aims to better measure liver health
Knowledge-focused CompletedThis study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Standing ultrasound spots hidden liver tumors better than lying down
Knowledge-focused CompletedThis study tested whether having patients stand during an ultrasound helps doctors see small liver tumors near the diaphragm that are often missed when lying down. Researchers scanned 95 people with confirmed liver lesions in three positions: standing, lying on their back, and ly…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New scan spots chemo damage to heart and muscles early
Knowledge-focused CompletedThis study tested whether a special MRI scan (31P-MRS) can detect early signs of damage to heart and muscle cells caused by chemotherapy drugs like doxorubicin. Twelve cancer patients scheduled for chemo underwent three scans over time. The goal was to see if the scan could measu…
Sponsor: UMC Utrecht • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Researchers measure breathing, strength, and quality of life in hospitalized endocrine patients
Knowledge-focused CompletedThis completed observational study at Uşak University examined 150 adults hospitalized in the endocrinology department. Researchers measured breathing, muscle strength, pain, fatigue, sleep quality, physical activity, balance, and nerve function. The goal was to better understand…
Sponsor: Uşak University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Sharper scans may make cancer radiation more precise
Knowledge-focused CompletedThis study tested a new cone-beam CT scanner that takes clearer pictures during radiation therapy for lung, liver, and breast cancers. 31 people participated to see if the new scanner reduces image blurring and improves accuracy. The goal is to help doctors target tumors more pre…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New scanner aims to sharpen cancer radiation targeting
Knowledge-focused CompletedThis study tested a new on-couch imaging system called HyperSight, which takes 3D X-ray pictures (CBCT) of cancer patients right before their radiation treatment. 46 adults with head/neck, chest, abdomen, or pelvic cancers received both the new HyperSight scan and a standard scan…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New nutrition training boosts oncology Nurses' skills in vietnam
Knowledge-focused CompletedThis study tested a co-designed nutritional training program for 20 oncology nurses in Vietnam. The program included a three-day workshop with theory and hands-on practice, focusing on managing diet-related side effects of cancer treatment like nausea and diarrhea. Researchers me…
Phase: NA • Sponsor: VinUniversity • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI model may personalize liver cancer care after surgery
Knowledge-focused CompletedThis study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study tests simple ways to track muscle loss in kids with cancer
Knowledge-focused CompletedThis study looked at whether it's possible to measure muscle mass and physical function in children (ages 8-21) with newly diagnosed solid tumors or lymphoma during cancer treatment. Researchers used simple tests like a 6-minute walk and a special drink to measure muscle, along w…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Cancer surgery recovery: quality of life under the microscope
Knowledge-focused CompletedThis study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…
Sponsor: University Hospital, Geneva • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
AI in cancer care: 7,151 people share their hopes and fears
Knowledge-focused CompletedThis study looked at how cancer patients, the general public, and healthcare professionals use and feel about large language models (like ChatGPT) for making cancer treatment decisions. Over 7,000 people from 30 countries completed a survey. The goal was to understand current usa…
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Can better Doctor-Patient bonds reduce cancer care disparities?
Knowledge-focused CompletedThis study looked at how trust and communication (called a therapeutic alliance) between Latino/a advanced cancer patients and their oncologists might affect care. Researchers interviewed 4 doctors and held focus groups with 10 patients to understand barriers and what helps build…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Silent threat: low albumin levels linked to worse outcomes in elderly cancer surgery
Knowledge-focused CompletedThis study looked at 330 older adults (65+) who had cancer surgery to see if low albumin levels before surgery led to more complications. Researchers compared patients with low albumin to those with normal levels, tracking problems like infections, hospital stay length, and ICU n…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New risk score may predict breathing complications after cancer surgery
Knowledge-focused CompletedThis study tested whether a tool called the ARISCAT score can predict lung complications (like pneumonia or collapsed lung) after major abdominal cancer surgery. Researchers followed 410 adults who had surgery under general anesthesia. The goal was to see if the score could help …
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Cancer patients help design better quality-of-life surveys
Knowledge-focused CompletedThis study aimed to improve how we measure quality of life in cancer patients whose disease is progressing. Researchers interviewed 20 patients, their carers, and healthcare professionals to learn their preferences on how often and in what way to collect this information. The goa…
Sponsor: University of Leeds • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Hepatitis & liver cancer risk explored in immigrant communities
Knowledge-focused CompletedThis study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Cancer Patients' work struggles revealed in new study
Knowledge-focused CompletedThis study looked at how cancer patients feel about returning to work while undergoing treatment. Researchers interviewed 20 patients to understand their needs and how work affects their sense of normalcy. The goal is to help nurses provide better support for work-related challen…
Sponsor: Centro di Riferimento Oncologico - Aviano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Ultrasound vs. MRI: which is better for catching liver cancer early?
Knowledge-focused CompletedThis study looked at 211 people with liver cirrhosis to see which screening method works better for detecting liver cancer: an ultrasound every 6 months or an MRI once a year. Participants received both tests, and researchers measured how often each test correctly found cancer. T…
Sponsor: JOON-IL CHOI • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for clues to why immunotherapy fails in most patients
Knowledge-focused CompletedThis study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Study reveals hidden burdens of cancer caregivers
Knowledge-focused CompletedThis study looked at the needs and challenges of family caregivers who help older adults (70+) with cancer. Researchers interviewed 78 caregivers to understand their social and personal situations, and tested a personalized support program with phone follow-ups. The goal was to s…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New drug tracking study offers no cure, but key insights for future cancer treatments
Knowledge-focused CompletedThis study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Thyroid cancer Drug's side effect on body mass measured in small study
Knowledge-focused CompletedThis completed study from the University of Pisa looked at how the thyroid cancer drug selpercatinib affects body composition. Fifteen adults on the drug had their lean mass and energy expenditure measured. The goal was simply to observe and gather data, not to test a new treatme…
Sponsor: University of Pisa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study tracks COVID vaccine durability in chronic illness patients
Knowledge-focused CompletedThis completed study followed 360 adults and children with chronic respiratory and other medical conditions to see how their immune systems responded to COVID-19 vaccines over 18 months. Researchers measured antibody, T cell, and B cell levels before vaccination and every 3 month…
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
Bile duct issues may shorten cancer treatment, study finds
Knowledge-focused CompletedThis study looked at medical records of 729 people in Japan with biliary tract cancer that could not be removed by surgery. Researchers wanted to see if bile duct problems during first treatment affected how long patients could stay on that treatment. The study did not test any n…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Which scanner spots the smallest tumors? new study puts two to the test
Knowledge-focused CompletedThis study tested two different PET-CT scanners to see which one is better at finding very small cancer spots (less than 1 cm) in patients. Twenty-four people with cancer each had two scans, one on each machine. The researchers then added virtual lesions to the images to compare …
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Mukbang watching studied as appetite booster for young cancer patients
Knowledge-focused CompletedThis study looked at whether children with cancer who watch mukbang (eating shows) have better appetite during hospital treatment. Researchers tracked 179 children's eating habits and video watching over several days. The goal was to see if there's a link that could help improve …
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Could T-DXd outperform standard care for multiple HER2-Positive cancers? new study investigates
Knowledge-focused CompletedThis study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New 3D method may improve tumor measurement accuracy
Knowledge-focused CompletedThis study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Quick checkup for cancer survivors: could a simple screener boost quality of life?
Knowledge-focused CompletedThis completed study tested a new tool called Life S-Can that quickly checks diet, exercise, sleep, and mental health in cancer survivors. 105 survivors used the tool and some received extra coaching from health experts. The goal was to see if the tool helps doctors give better s…
Phase: NA • Sponsor: Fundació d'investigació Sanitària de les Illes Balears • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
PET scan study hints at new hope for tough gut cancer
Knowledge-focused CompletedThis study looked at 30 adults with a rare, fast-growing type of gut cancer called poorly differentiated neuroendocrine carcinoma. Researchers used a special PET scan (68Ga-DOTATATE) to measure how much of a protein called somatostatin receptor is present on tumors. The goal was …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists peer into liver cancer cells to unlock secrets
Knowledge-focused CompletedThis study looked at liver cancer cells from 30 patients to understand how they differ from healthy cells. Researchers isolated these cells to create 3D lab models called organoids. The goal was to learn more about the behavior and genetics of liver cancer, not to test a new trea…
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
HIV cancer study reveals who gets sick and why
Knowledge-focused CompletedThis study looked at 460 people with HIV to see what types of cancer they have and why some choose to join cancer clinical trials. Researchers tracked cancers like Kaposi sarcoma, lymphoma, and HPV-related tumors. They also used surveys to learn how HIV and cancer treatments affe…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Researchers track skin reactions in cancer patients on newer drugs
Knowledge-focused CompletedThis study looked at skin problems caused by targeted cancer therapies. Researchers followed 141 cancer patients starting these treatments, recording any skin reactions through exams and photos. The goal was to better understand why these side effects happen and how to manage the…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
AI reads MRI scans to predict liver cancer survival
Knowledge-focused CompletedThis completed study looked at 169 patients with a type of liver cancer called intrahepatic cholangiocarcinoma. Researchers used MRI scans and machine learning to measure scar tissue and a protein linked to tumor growth. The goal was to see if these features could predict how lon…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Massive data dive on elderly cancer patients reveals care gaps
Knowledge-focused CompletedThis study gathered information from nearly 3,000 cancer patients aged 65 and older to learn more about their health, living situations, and the care they receive. No new treatments were tested. The goal was to create a database that helps doctors and researchers better understan…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New model helps surgeons choose best operation for rare liver cancer
Knowledge-focused CompletedThis study tested a computer model that helps surgeons decide the best type of surgery for patients with a rare form of liver cancer that has spread into the bile ducts. The model uses patient scans and medical history to recommend whether to remove part of the bile duct or just …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New tools aim to measure stigma in kids with cancer
Knowledge-focused CompletedThis completed study involved 633 participants and aimed to develop two clinical tools to identify and measure stigma experienced by children with cancer and their caregivers. Researchers worked in the United States, Guatemala, and Jordan to ensure the tools are culturally releva…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Study reveals hidden struggles of caring for dying loved ones at home
Knowledge-focused CompletedThis study looked at the emotional and practical challenges faced by patients with incurable cancer and their caregivers when planning to return home for end-of-life care. Researchers measured how each person perceived the burden, using surveys and statistical analysis to find fa…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Money stress in young cancer patients: new study offers help
Knowledge-focused CompletedThis study aimed to understand and address financial stress in teens and young adults (ages 15-39) recently treated for cancer. Researchers tested a financial education and navigation program to see if it was helpful and practical. The study involved 26 participants and focused o…
Phase: NA • Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Real-world study reveals how well new liver cancer combo works in patients with cirrhosis
Knowledge-focused CompletedThis study looked at how safe and effective a combination of two drugs (Atezolizumab and Bevacizumab) is for people with liver cancer and cirrhosis, compared to standard pills (tyrosine kinase inhibitors). Researchers followed 38 patients to see how long they lived and how their …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Talking about tomorrow: study explores End-of-Life care conversations for cancer patients
Knowledge-focused CompletedThis study looked at how patients with advanced cancer respond to being offered a conversation about their future care preferences. Researchers invited 71 patients to discuss their wishes and tracked who took part. The goal was to learn more about what helps patients feel ready t…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New blood test spots silent spread of bile duct cancer before surgery
Knowledge-focused CompletedThis study tested whether a blood test that looks at tiny particles called exosomes can find cancer that has spread but is not visible on scans in people with a type of bile duct cancer (intrahepatic cholangiocarcinoma). The goal was to help doctors know who needs stronger treatm…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Michigan study tests ways to boost genetic testing in cancer patients
Knowledge-focused CompletedThis study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
CT scan clues may guide better liver cancer care
Knowledge-focused CompletedThis study looked at 324 adults with intermediate-stage liver cancer to see if CT scan features could predict how well they would respond to a combination treatment of targeted therapy and a procedure that blocks the tumor's blood supply. The goal was to find out if certain scan …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Lymphoma Patients' brain function under microscope after new cell therapy
Knowledge-focused CompletedThis study followed 60 adults with diffuse large B-cell lymphoma or transformed lymphoma who received commercial axi-cel therapy. Researchers measured changes in memory, attention, executive function, hand strength, and quality of life using surveys and cognitive tests. The goal …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New program aims to ease financial burden for young cancer survivors
Knowledge-focused CompletedThis study tested a program called FinFit to help adolescent and young adult cancer survivors deal with money problems caused by their illness. Researchers interviewed 16 people from community cancer clinics to design and improve the program. The goal was to figure out the best w…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC